Clinical Trial

Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the immunogenicity and safety of TVAX-008 injection in antiviral untreated/untreated chronic hepatitis B patients with HBsAg≤20 IU/mL, or HBsAg negative and no seroconversion through an investigator-initiated clinical study.
Trial Details
NCT Number NCT07204236
Lead Sponsor Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Conditions Chronic Hepatitis B
Enrollment 20 participants
Start Date 2024-01-18
Primary Completion 2025-03-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-02